Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Common Equity (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Common Equity for 16 consecutive years, with $50.4 million as the latest value for Q3 2025.

  • Quarterly Common Equity rose 10.19% to $50.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $50.4 million through Sep 2025, up 10.19% year-over-year, with the annual reading at $43.0 million for FY2024, 16.33% down from the prior year.
  • Common Equity for Q3 2025 was $50.4 million at Xtant Medical Holdings, up from $48.5 million in the prior quarter.
  • The five-year high for Common Equity was $54.7 million in Q3 2023, with the low at $28.1 million in Q2 2022.
  • Average Common Equity over 5 years is $39.4 million, with a median of $34.2 million recorded in 2022.
  • Peak annual rise in Common Equity hit 172.31% in 2021, while the deepest fall reached 31.98% in 2021.
  • Over 5 years, Common Equity stood at $30.9 million in 2021, then rose by 10.65% to $34.2 million in 2022, then skyrocketed by 50.27% to $51.3 million in 2023, then decreased by 16.33% to $43.0 million in 2024, then rose by 17.27% to $50.4 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $50.4 million, $48.5 million, and $43.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.